IGF-1 DES

A truncated form of IGF-1 lacking the first three N-terminal amino acids (Gly-Pro-Glu). This modification eliminates binding to most IGF binding proteins, making it approximately 10 times more potent than native IGF-1 at the receptor level. Its extremely short half-life makes it ideal for targeted, site-specific intramuscular injections to promote localized muscle growth.

• Binds IGF-1R with high affinity but minimal IGFBP interaction, resulting in maximal receptor activation
• Potent PI3K/Akt/mTOR activation for protein synthesis at the injection site
• Stimulates local satellite cell proliferation and myoblast differentiation
• Short half-life confines most biological activity to the local tissue environment

• Active or history of malignancy
• Diabetes or insulin-dependent conditions
• Pregnancy or breastfeeding
• Under 25 years of age

Store at 2–8°C (36–46°F) for up to 3 months. For long-term storage, keep at -20°C (-4°F). Once reconstituted, refrigerate and use within 14 days. Do not freeze after reconstitution.

Reconstitute with 0.6% acetic acid for optimal stability. Bacteriostatic water is acceptable but may reduce shelf life. Gently swirl to dissolve.

Des(1-3) IGF-1 was originally identified as a naturally occurring brain IGF-1 variant. In vitro studies demonstrate 5-10x greater mitogenic potency than full-length IGF-1 in myoblast cultures. Animal studies confirm enhanced muscle protein synthesis with local administration. Research in dairy cattle showed significant mammary growth effects. It remains a research compound with no clinical trials in humans for muscle indications.